Introduction
Successful migration of neutrophils (PMNs) from the circulation to the airway lumen is critical for pulmonary host defense, but also responsible for bystander tissue injury that underlies a wide array of acute and chronic lung diseases. PMN trafficking to the lung differs fundamentally from that in other tissues (1) . Integrin-dependent firm adhesion to endothelium and diapedesis occur in alveolar capillaries, after which PMNs are thought to track along interstitial fibroblasts, finally passing paracellularly through the epithelium at the junction of alveolar epithelial type 1 (AT1) and type 2 (AT2) cells (2) . Studies over the past two decades have loosely categorized the PMN influx to different airway exposures on the basis of the PMN integrins utilized. Thus, trafficking in response to lipopolysaccharide (LPS), E. coli, and P. aeruginosa is primarily CD18 (2 integrin)-dependent, whereas that to S. pneumoniae and CXCL1 is CD18-independent and CD29 (1 integrin)-dependent (3) . Endothelial ligands that interact with PMN integrins to control vascular egress have been well-described (3) . Epithelial membrane proteins also regulate transepithelial migration (TEM) via cognate interactions with PMNs (4) , and studies suggest that transepithelial, rather than transendothelial passage of PMNs is linked to epithelial wounding, catastrophic lung damage, and mortality (4, 5) . Targeting pulmonary TEM might conceivably offer effective and selective strategies for PMN-mediated lung disease. However, to date, the few epithelial membrane proteins that have been proposed to regulate pulmonary TEM (e.g., intercellular adhesion molecule [ICAM]-1; CD47) have largely been extrapolated from in vitro studies of intestinal epithelium (4, 6) . AT1 cells are best known for their roles in solute transport and gas exchange. Whether AT1 cells regulate PMN TEM is unknown. Whether TEMregulatory proteins are coordinated in alveolar epithelial cells is also an open question.
Epithelial membrane protein 2 (EMP2) is a member of the tetraspan superfamily of membrane proteins. Although its mechanism of action remains somewhat obscure, EMP2 is thought to promote the recruitment of select integrins (61, v3), adhesion molecules (ICAM-1), and signaling proteins to plasma membrane raft microdomains, and to downregulate caveolins, thereby reciprocally augmenting rafts and reducing caveolae (7) (8) (9) (10) . In cancer cells, EMP2 may serve as a platform for integrin signaling, supporting cell adhesion to extracellular matrix (ECM) and other cytoskeletal functions (11) . Of interest, in rodents and humans, EMP2 is by far most highly expressed in the lung (biogps.org), where EMP2 protein has been shown to be highly expressed in AT1 cells, but absent in AT2 cells and alveolar macrophages (AMs) (12) . To date, however, no function has been assigned to EMP2 in lung biology, and few roles have been identified for AT1 cells in regulation of immune responses.
Here, we show that Emp2 -/-mice exhibit deficient alveolar PMN influx in response to a wide range of CD18-dependent and -independent inhaled exposures. We provide evidence that this is due to deficient PMN TEM, arising from a deficit in epithelial function. Emp2 -/-AT1 cells are deficient in lipid rafts and surface adhesion molecules and Emp2-deficient epithelial cells support reduced PMN TEM in vitro. Mutagenesis of EMP2 reveals that its functions are dependent upon two putative cholesterol-binding sequences, suggesting that EMP2 serves a critical raft scaffolding function. EMP2 support of adhesion molecule display and PMN TEM is dependent upon epithelial cell caveolin-2. Emp2 -/-mice have reduced lung injury and enhanced survival during bacterial pneumonia. Taken together, we identify EMP2 as a master regulator of AT1 membrane organization that instructs the terminal step of PMN traffic into the alveolus.
Results

EMP2 regulates TEM of PMNs into the alveolar space in response to diverse exposures
EMP2, a tetraspan membrane protein, is reportedly expressed in AT1, but not AT2 cells nor AMs in rat and human lung (12) . We found that Emp2 transcripts were readily detected in AT1 (CD45 − CD31 − CD34 − EpCAM int T1α + MHCII − ), AT2 (CD45 − CD31 − CD34 − EpCAM int T1α − MHCII + ), and airway epithelial cells (CD45 − CD31 − CD34 − EpCAM hi MHCII − ) sorted from murine lung, albeit with relative enrichment in the former cell type (Supplemental Figure 1) . Specific signal for EMP2 protein was, however, observed only in AT1 cells (Supplemental Figure 2 ), suggesting post-transcriptional regulation. In vivo, Emp2 RNA and protein were both transiently downregulated in mouse lung following LPS inhalation, with a progressive return toward baseline commencing after 24h post-exposure (Supplemental Figure 3A-B ). EMP2 was induced in a time-dependent fashion in both mouse and rat primary AT2 cells during in vitro transdifferentiation into AT1-like cells (Supplemental Figure 3C-D) . Surveying a panel of pulmonary epithelial cell lines, we found, somewhat surprisingly, that EMP2 protein was expressed in several airway lines (Calu-3, Beas-2B, H292) (Supplemental Figure 3E ), but undetectable in two AT1-like cell lines (E10, Let1) (not shown).
Given that EMP2 supports lipid raft assembly (8, 9) and rafts regulate Toll-like Receptor (TLR) signaling (13), we hypothesized that EMP2 might be required for the pulmonary innate immune response. To test this, we studied Emp2-null mice (14) . Naïve 8-12 week old Emp2 -/-mice had no overt changes in lung histology (not depicted), nor changes in resident AM number or bronchoalveolar lavage fluid (BALF) concentration of total protein or cytokines (Supplemental Pulmonary expression of the alternate tetraspan family members Emp1, Emp3, and Pmp22 was also unaltered (Supplemental Figure 4D ). Immunoblotting revealed a modest reduction in the tight junction protein occludin in lung homogenates of naïve Emp2 -/-mice, but no discernible change in expression of JAM-1 or claudins-3, 12, or 18 (Supplemental Figure 4E) . Upon inhalational challenge, Emp2 -/-mice exhibited a striking reduction in alveolar neutrophilia triggered by LPS, Gram-negative bacteria (K. pneumoniae, P. aeruginosa), and Gram-positive bacteria (S. pneumoniae) (Figure 1A-D) , suggesting a wide-ranging deficit in innate immunity.
Pretreatment of Emp2 +/+ mice i.t. with an anti-EMP2 scFv antibody fragment reported to inhibit EMP2 (15) also reduced LPS-induced airspace neutrophilia compared with control treatment (Supplemental Figure 5) . Given that TLR activation in AMs and alveolar epithelial cells induces cytokines and chemokines that then attract circulating PMNs, we initially predicted that Emp2 -/-mice would have a reduction in these mediators in the airspace. However, BALF concentrations of cytokines and chemokines of established importance to PMN lung trafficking (3) were all normal 2h after LPS inhalation, a time point prior to substantial PMN influx ( Figures   1A, 1E ). Emp2 +/+ and Emp2 -/-mice also had equivalent numbers of circulating PMNs in the naïve, LPS-exposed, and K. pneumoniae-exposed state (Supplemental Figure 6 ), suggesting no defect in supply of peripheral PMNs. Collectively, this suggested to us either a cell-intrinsic or -extrinsic deficit in migration of circulating PMNs to the airspace. Given that Emp2 transcripts are minimally detectable in murine PMNs (>10-fold lower in PMNs than in AMs by RNA-Seq [Immgen.org]), we hypothesized that a cell-extrinsic mechanism was more likely.
In support of deficient PMN trafficking in Emp2 -/-mice, reduced influx of PMNs to the airspace was also observed after intrapulmonary inoculation of naïve mice with the chemokine CXCL1 ( Figure 1F) . No differential secondary induction of CXCL5, reportedly produced by AT1 cells under some conditions (16) , was observed in the airspace of CXCL1-inoculated Emp2 -/-mice, suggesting that the differential PMN trafficking was a primary response to intra-alveolar CXCL1.
Notably, intraperitoneal injection of CXCL1 elicited equivalent PMN influx into the peritoneal 7 cavities of Emp2 +/+ and Emp2 -/-mice, formally demonstrating intact intrinsic chemotactic function of Emp2 -/-PMNs in vivo ( Figure 1G ).
Chimeric mice made by bone marrow transfer revealed that EMP2 deletion in radioresistant lung cells, but not radiosensitive (i.e., hematopoietic) cells was sufficient to confer deficient alveolar PMN influx in response to inhaled LPS (Figure 2A ). This finding, in conjunction with the i.t. CXCL1 results and expression pattern of EMP2 in the murine lung, suggested that a defect in Emp2 -/-AT1 cells might be causing deficient TEM of PMNs from the pulmonary interstitium into the alveolar lumen. Supporting this idea, we found a ~2-fold increase in PMNs in the parenchyma of perfused Emp2 -/-lungs after LPS challenge ( Figure 2B ). Intravital PMN labelling with i.v. antibody to distinguish endovascular from interstitial (extravascular) PMNs in perfused and airway-lavaged lungs confirmed a significant increase in interstitial PMNs in Emp2 -/-mice following LPS (Figure 2C) , pointing to a deficit in PMN transit from interstitium to airspace lumen. This was further corroborated by live lung slice imaging, which interestingly revealed a marked increase in interstitial PMNs both in the bronchovascular sheath surrounding, and in the wall of, small airways ( Figure 2D ). This result raises the possibility of an epithelial abnormality at the level of small airways in Emp2 -/-mice. Given that multiple airway epithelial cell lines do express EMP2 (Supplemental Figure 3C) , it is possible that EMP2 protein is expressed in the small airway epithelium in vivo but below the detection limit of our immunofluorescence antibody. Alternatively, the distribution of interstitial PMNs in the Emp2 -/lung could conceivably arise from abnormal intra-tissue PMN trafficking that initiates from a primary defect at the level of the terminal airspaces (e.g., necessitation up the bronchovascular sheath). Suggesting that epithelial EMP2 deficiency is sufficient to attenuate PMN TEM, we found a marked defect in migration of primary human PMNs in the physiological basolateral-to-apical direction through a monolayer of EMP2-silenced Calu-3 cells in response to the chemotactic peptide N-formyl-met-leu-phe (fMLP) (Figure 2E ).
EMP2-deficient mice have improved survival during bacterial pneumonia
PMNs are critical for bacterial killing during pneumonia, but also cause deleterious bystander injury to the pulmonary epithelium (4) . Indeed, overexuberant alveolar neutrophilia during pneumonia can compromise survival despite improving bacterial clearance (17, 18) . To what degree PMNs eradicate bacteria in the alveolar lumen versus interstitium during pneumonia is unclear, but successful passage of bacteria through damaged pulmonary epithelium is associated with extrapulmonary dissemination and mortality (19) . We found that there was no change in bacterial burden in whole (non-lavaged) lung homogenates of Emp2 -/-mice during infection with K. pneumoniae (Figure 3A) , and no consistent change in bacterial counts in BALF (not shown), collectively suggesting grossly intact bacterial clearance in the infected Emp2 -/lung. Of interest, Emp2 -/-mice, however, exhibited increased survival during lung infection with K. pneumoniae compared to wild type counterparts ( Figure 3B ). This was associated with attenuated injury to the alveolocapillary barrier, as indicated by dramatic reductions in BALF protein, albumin, and IgM ( Figure 3C ).
Aiming to determine whether preservation of the epithelial barrier due to reduced PMN TEM was attenuating extrapulmonary bacterial dissemination in Emp2 -/-mice, we surveyed the peripheral circulation. At 48h post-infection, the time point of initial separation of survival curves between Emp2 +/+ and Emp2 -/-mice (Figure 3B) , Emp2 -/-mice had lower serum IL-6 and TNF ( Figure 3D) , denoting decreased systemic inflammation. However, there was no significant change in bloodstream or splenic bacterial burden (Supplemental Figure 7) , arguing against reduced sepsis as an explanation for the decreased cytokines and mortality. Of note, Emp2 -/-mice displayed marked reductions in neutrophilic pulmonary consolidation and associated tissue damage on histopathologic analysis (Figure 3E, Supplemental Figure 8 ). Taken together, this finding suggests that, during pneumonia, the lungs are the source of the differential serum cytokine levels in Emp2 +/+ and Emp2 -/-mice, and that Emp2 -/-mice have relative protection from a respiratory death (i.e., respiratory failure from acute lung injury).
In order to test whether Emp2 -/-mice might nonetheless be susceptible to pathogen overgrowth and dissemination after higher burden infections, we next inoculated the lungs of Emp2 +/+ and Emp2 -/-mice with 4000 CFU of K. pneumoniae. Of interest, at 48h post-infection, we observed a significant reduction in bacterial burden in the lungs, bloodstream, and spleen of Emp2 -/-mice ( Supplementary Figure 9 ), suggesting enhanced pathogen clearance in the lungs and reduced extrapulmonary dissemination. Collectively, these findings suggest that anti-microbial host defense is impacted by EMP2 in a dose-dependent fashion, and that EMP2 deficiency does not compromise, but may rather enhance pathogen clearance at higher infectious inocula.
EMP2 deficiency dysregulates epithelial display of adhesion molecules
We next sought to define the mechanism whereby EMP2 regulates transit of PMNs into the alveolus. Studies deriving from intestinal epithelium have suggested that PMN 2 integrins initially engage fucosylated glycoprotein(s) on the basolateral epithelial surface, after which non-2 integrin PMN proteins interact with CD47 and other epithelial proteins during paracellular transit (6) . Very few epithelial regulators of TEM have been specifically validated in the lung (4).
v3 integrin, reportedly upregulated by EMP2 in cell lines (10) , has been implicated in LPSinduced alveolar neutrophilia (20) . The β2 integrin ligand ICAM-1, also upregulated by EMP2 in cell lines, has also been implicated in TEM into both the intestinal and alveolar lumen (21, 22) .
As S. pneumoniae-and CXCL1-induced alveolar neutrophilia are reportedly fully, and LPSinduced neutrophilia, partially, CD18-independent (3, 23), we initially reasoned that dysregulation of CD18-independent ligands in Emp2 -/-epithelium was the most parsimonious explanation for our findings. However, given that LPS-induced alveolar neutrophilia is estimated to be only ~20% CD18-independent (3), the marked PMN reduction observed in LPS-and Gram-negative bacteria-exposed Emp2 -/-lungs (Figure 1A -C) suggested that dysregulation of ligands for both CD18 and other PMN proteins was likely present in Emp2 -/-epithelium.
Using flow cytometry, we found that surface display of CD47 was increased on AT1 cells of 
EMP2 is required for AT1 cell raft integrity
EMP2 localizes to lipid rafts in cell lines and has been proposed to support lipid raft assembly and to specify proteins for rafts by acting as a scaffolding protein (9, 11) . The multiple adhesion molecule changes in Emp2 -/-AT1 cells, including proteins that localize to rafts (4, 8) , suggested to us raft dysregulation as a potential unifying mechanism. Consistent with this, we found that primary murine AT1-like cells transdifferentiated in vitro from mouse lung digests displayed a significant reduction in surface binding of cholera toxin B (CtB) (Figure 5A) , a ligand for GM1 and other raft-localized gangliosides that has been used widely as a metric for raft mass (13) .
Changes in CtB signal of similar or smaller magnitude in other cell systems have been shown to track with biologically significant changes in raft function (24, 25) . Raft mass was similarly reduced in EMP2-silenced Calu-3 cells (Figure 5B -C) and H292 cells ( Figure 5D ). Conversely, in Let1 cells, an AT1-like cell line (26) in which we could not detect expression of native EMP2 protein by immunoblot (not shown), overexpression of EMP2 augmented CtB binding, suggesting an increase in raft mass ( Figure 5E ).
Localization of EMP2 to rafts has been reported to be cholesterol-dependent (9, 11 ), suggesting that direct or indirect interactions of EMP2 with raft cholesterol may be necessary for its raftscaffolding functions. Cholesterol recognition/interaction amino-acid consensus (CRAC) motifs, with the sequence L/V-X 1-5 -Y-X 1-5 -K/R (where X 1-5 is 1 to 5 of any amino acid and the central tyrosine is proposed to be critical) and inverted CRAC ('CARC') motifs are two amino acid sequences by which membrane proteins are proposed to bind to cholesterol (27) . Both motifs are proposed to stabilize cholesterol in membranes to support assembly of rafts (28) . The tetraspan family member PMP22 has a CRAC motif in its fourth transmembrane domain (29) .
Given this, we manually inspected EMP2, and noted it to have one potential CRAC sequence in, plus two potential CARC sequences near, its predicted fourth transmembrane domain (Supplemental Figure 11 ). Aiming to test whether one or more of these sequences are required for EMP2 support of raft assembly, we mutated the central tyrosine residue of the two CARCs nearest the transmembrane domain (Y144, Y146), as well as that of the CRAC motif (Y165) and expressed these mutants, along with WT EMP2, in (EMP2-null) Let1 cells. Notably, the Y144A and Y165A EMP2 mutants failed to support CtB binding in Let1 cells to the degree of WT EMP2 (Figure 5F ). This suggests that interactions of EMP2 with cholesterol in its fourth transmembrane domain are required for its raft-supporting function in AT1 cells, potentially through promoting EMP2 localization to rafts. By contrast, although overexpression of WT EMP2 increased ICAM-1 surface display in Let1 cells, equivalent upregulation was observed with the CARC and CRAC mutants (Supplemental Figure 12 ), suggesting that, at least in this cell line and overexpression system, cholesterol interactions may not be required for EMP2 support of adhesion molecule display.
EMP2 regulates epithelial adhesion molecules and TEM through caveolin-2
From its location in rafts, EMP2 is thought to act in trans on caveolae, distinct membrane microdomains whose flask-like shape is driven by hetero-oligomerization of the membrane proteins caveolin-1 and -2 (30) . Through somewhat obscure mechanisms, EMP2 reduces expression of both caveolins (9) . Caveolins, like EMP2, regulate other membrane proteins through scaffolding and signaling interactions (30) . In renal podocytes, EMP2 silencing induces cell injury through upregulation of caveolin-1 (31) . Given this, we hypothesized that, in AT1 cells, EMP2 deficiency might alter adhesion molecules and PMN TEM via dysregulation of the caveolins.
Consistent with prior reports in Emp2-silenced cell lines (9), we found that caveolins-1 and -2 were upregulated in Emp2 -/-lung homogenates (Figure 6A ). Although the upregulation was modest, this may not be unexpected given our finding that EMP2 is expressed in only a subset of pulmonary cells. A more robust upregulation was indeed confirmed upon EMP2 silencing in Calu-3 cells (Figure 6B) . Conversely, ectopic expression of EMP2 in CMT 64 cells downregulated both caveolins (Figure 6C ).
Using Calu-3 cells as a model system, we sought to test whether the effects of EMP2 deficiency we had identified in epithelial cells were dependent upon caveolins. Although the two caveolins 13 have distinct functions, the lung abnormalities of Cav1 -/-mice (i.e., hypercellularity) have been attributed to caveolin-2 deficiency (32) . Given this and our finding that Calu-3 cells express robust caveolin-2 but not caveolin-1 protein on immunoblot (not depicted), we focused our interventions on caveolin-2. Caveolin-2 silencing by shRNA abolished the relative upregulation of this protein observed in EMP2-deficient Calu-3 cells (Figure 6D) . Of interest, caveolin-2 silencing rescued the reduced surface display of both ICAM-1 and 3-integrin observed in EMP2-deficient Calu-3 cells but did not reverse their modest upregulation of CD47 (Figure 6D) . This finding suggests that some but not all of the membrane-regulatory effects of EMP2 are mediated via caveolins. Whether this reflects distinct membrane microdomain (i.e., caveolar) partitioning between CD47 and ICAM-1/3-integrin or an alternate mechanism remains unclear.
In order to test more directly whether EMP2 regulates PMN TEM in a caveolin-dependent fashion, we engineered doxycycline-inducible caveolin-2-silenced Calu-3 cells on both the EMP2-sufficient and -deficient background and cultured them to confluence for PMN transmigration studies. Both caveolin-2 silencing constructs depleted caveolin-2, neutralizing its relative upregulation in EMP2-deficient cells (Figure 6E) . Of interest, the caveolin-2 silencing constructs augmented PMN transit through EMP2-deficient Calu-3 monolayers. The reduction in PMN transmigration observed with EMP2 knockdown was no longer seen in caveolin-2silenced Calu-3 cells (Figure 6E) . This finding indicates that the reduction in PMN TEM observed in EMP2-deficient cells is caveolin-dependent.
Discussion
Trafficking of PMNs to the lung has been studied for decades, but the extent to which the pulmonary epithelium serves as a final gatekeeper to the airspace for PMNs that have exited the vasculature, as well as the degree to which epithelial control of PMN trafficking is a regulated and coordinated event, has remained largely undefined. Here, we identify EMP2, a gene highly expressed in the lung but previously of unknown function in lung biology, as a master regulator of the terminal entry of PMNs into the airspace lumen. Our studies suggest that EMP2 supervises display of adhesion molecules on AT1 cells through organization of membrane microdomains, thereby ensuring cognate interactions for PMNs in transit.
Planar rafts and flask-shaped caveolae are distinct cholesterol-enriched membrane microdomains that both serve as platforms for protein-protein and lipid-protein interactions (13) .
Caveolae, whose invaginated morphology derives from caveolin-1/2 heterodimers, are found in a subset of cell types (e.g., AT1 cells, endothelial cells, fibroblasts). In these cells, it is thought that caveolae co-exist with spatially segregated rafts, but the relative function, protein repertoire, and crosstalk between these two microdomains remains poorly understood. Indeed, given that membrane fractionation methods fail to distinguish between rafts and caveolae, and sophisticated techniques such as immunogold electron microscopy are instead required, many reports have almost certainly conflated the two microdomains (13) . In the case of EMP2, it has been shown that it does not colocalize with caveolae or caveolins, but rather is specific for rafts, from which location it supports the levels of other raft proteins, likely through scaffolding or other interactions (9) .
Of interest, caveolin-1 is not only necessary, but also sufficient for biogenesis of caveolae, as heterologously expressed caveolin-1 binds and clusters specific membrane lipids (33) , inducing formation of invaginated caveolae (34) . Upregulation of caveolin-1 dysregulates endocytosis of caveolae (35) , suggesting that the function of existing caveolae is also sensitive to changes in caveolin-1 expression. In turn, several proteins have been identified that modify caveolae through direct or indirect effects on caveolins (35) (36) (37) . Among these, EMP2 reportedly suppresses expression of caveolin-1 and -2 at the mRNA and protein level (9), thereby impacting caveolin-dependent signaling (38) . The protein-level effect may be through lysosomal delivery of caveolin-1 (38) . Taken together, EMP2 appears to coordinate different membrane microdomains, reciprocally supporting localization of proteins to rafts and suppressing caveolar signaling.
Here, we show for the first time that EMP2 support of raft mass (i.e., GM1 signal) is contingent upon two putative cholesterol-binding sequences that are predicted to lie in or near its fourth transmembrane domain. This finding suggests that EMP2 may serve as a molecular scaffold that physically intermediates association of cholesterol with proteins in rafts. Our studies were not designed to discriminate the raft vs. caveolar localization of adhesion molecules in AT1 cells; nor does cell surface display as quantified by flow cytometry clarify whether proteins have been displaced from their native microdomains. Our finding that CD47 dysregulation in EMP2deficient cells was independent of caveolin-2 is consistent with prior reports that CD47 is raftresident (18) . Conversely, the caveolin-2-dependence of ICAM-1 dysregulation that we observed in EMP2-deficient cells is consistent with its reported caveolar localization (30); the inverse relationship we found between it and caveolin is reminiscent of the caveolar protein HER2, whose cell surface levels are reportedly reduced by caveolin-1 overexpression and stabilized by caveolin-1 silencing (39) . Finally, our finding that 3 integrin is downregulated in EMP2-null epithelial cells is consistent with prior reports that EMP2 and v3 are physically associated in endometrial cell membranes (10) ; however, the caveolin-2-dependence of this downregulation that we observed is perhaps unexpected.
Taken together, we speculate that EMP2 coordinates adhesion molecule display in different membrane microdomains of AT1 cells through both direct and indirect mechanisms. Although we originally aimed to test whether mutagenesis of CRAC/CARC sequences in murine EMP2 impairs PMN TEM, we were unable to do so due to failure of monolayers of two EMP2-deficient murine alveolar epithelial cell lines (Let1, CMT 64) to culture tightly enough to support an effective chemokine gradient (not depicted). In the end, our Calu-3 system indicates that the deficit in TEM conferred by EMP2 deficiency is caveolin-2-dependent and that it tracks with downregulation of ICAM-1 and 3 integrin display. The magnitude of change in individual adhesion molecules in EMP2-deficient cells is modest. We speculate, however, as is supported by the TEM studies, that, together, the coordinate dysregulation of multiple surface proteins is sufficient to compromise interactions of epithelial cells with migrating PMNs. Of potential interest, occludin, which we found to be reduced in naïve Emp2 -/-lung homogenates, has also been reported to support TEM (40) . As PMN TEM is not abolished in Emp2 -/-mice, we conclude that EMP2 is not indispensable for PMN transit, but instead serves as a modifier, tuning cell traffic through its effects on the AT1 membrane. Given the importance of PMNs to environmental responses, it is perhaps unsurprising that redundancy is built into PMN trafficking. We speculate that additional raft scaffolding proteins (e.g., flotillins (13, 41) ) may contribute to adhesion molecule display in AT1 cells. In support of this, flotillin-2 is reported to regulate integrin trafficking in epithelial cells (42) . Future studies using targeted proteomics may be warranted to better define the extent of changes in the membrane protein complement of EMP2-null epithelial cells, and the subset of these changes that are either mediated via the caveolin proteins and/or sensitive to CRAC/CARC mutagenesis.
The finding that Emp2 -/-mice have reduced intra-and extrapulmonary bacterial burden after lung infection with a large inoculum (4000 CFU; Supplemental Figure 9 ) is particularly intriguing. As lung and bloodstream bacterial counts were equivalent between Emp2 +/+ and Emp2 -/-mice at lower inocula, we conclude that there is a pathogen threshold -and associated lung injury threshold -above which EMP2 deficiency augments host defense. Reduced PMNdependent injury to the respiratory epithelium in high inoculum-infected Emp2 -/-mice may improve bacterial compartmentalization in the lung, decreasing extrapulmonary dissemination.
While the explanation for improved bacterial clearance in the high inoculum-infected Emp2 -/lung is less evident, we speculate that it too may arise from improved compartmentalization in the airspace. This may allow for more efficient in situ killing in the alveolus, perhaps further buttressed by increased numbers of subepithelial (interstitial) PMNs (Figure 2B-C) positioned to address bacteria that do penetrate the epithelium.
Caveolins are widely expressed in the murine lung, including in AT1 cells, endothelial cells, alveolar macrophages, and infiltrating PMNs (43) . Caveolin-1-null mice, which are also caveolin-2-deficient (44), have abnormal pulmonary histopathology (44, 45) and reduced lung injury in response to LPS (46) . To our knowledge, PMN TEM has not been studied in these mice; instead, their pulmonary phenotypes have been largely ascribed to changes in endothelial (47) and PMN (48) functions. Our findings in Emp2 -/-mice (which we show have caveolin upregulation in the lung), suggest that future studies of mice with pulmonary epithelial-targeted caveolin overexpression may be warranted.
Our findings do not rule out potential roles for EMP2 in non-epithelial cell types of the lung.
Although EMP2 is expressed by NIH 3T3 fibroblasts (7), we did not evaluate EMP2 expression by pulmonary fibroblasts. PMNs are thought to extensively contact fibroblasts and ECM molecules during migration through the pulmonary interstitium (2) . Given this, we cannot formally exclude the possibility that interstitial accumulation of PMNs in the Emp2 -/-lung arises in part from altered integrin ligand display on interstitial fibroblasts or altered ECM composition.
Mouse lung endothelial cells express EMP2 mRNA (http://bis.zju.edu.cn/MCA/search.html).
However, the increase of interstitial PMNs in LPS-exposed Emp2 -/-lung, taken together with the decrease in alveolar PMNs, argues against dysregulated endothelium as a sufficient cause for the PMN trafficking defect. In the setting of K. pneumoniae, the overall reduction in PMNs we observed in Emp2 -/-lungs 48h post-infection ( Figure 3E ) could conceivably arise from dysregulated endothelial adhesion molecules; thus, future studies involving cell-specific Emp2 deletion may thus be warranted to resolve whether endothelial EMP2 contributes to PMN trafficking in some settings (e.g, live pathogen exposures, later time points). Finally, although we found no detectable expression of EMP2 by AMs in the naïve murine lung and our bone marrow chimera data point to EMP2 deficiency in non-hematopoietic cells as responsible for the PMN trafficking deficit, our data do not exclude the possibility that EMP2 may be upregulated in AMs during chronic inflammation and carry out roles in that cell type. Indeed, a recent report indicates that EMP2 is upregulated in macrophages by mycobacteria (49) .
We speculate that EMP2 may regulate much wider-ranging functions of AT1 cells in lung biology, and may perhaps have been evolutionarily selected for these other functions, given that Emp2 -/-mice fare better during bacterial pneumonia. Given that alveolar epithelial cells adhere to and migrate upon fibronectin via vβ3 (50), EMP2 may support epithelial repair in the injured lung. EMP2 may also possibly modify AT1 adhesive preference for ECM through control of integrin trafficking, as has been reported in cell lines (7) , and may thus also alter outside-in signaling from the ECM in AT1 cells. In HEK293 cells, EMP2 binds to and augments function of P2X7 (51), a purinergic receptor that in AT1 cells interacts with claudin-18 to potentially regulate the alveolar epithelial barrier (52) . Whether AT1 EMP2 regulates the alveolar epithelial barrier through interactions with P2X7 thus warrants investigation. Given that caveolins and caveolae play key roles in cell signaling, viral entry, and cell tolerance to mechanical stress (53), EMP2 may conceivably regulate these key events in AT1 cells through control of caveolin expression.
Finally, given that other leukocyte types (i.e., eosinophils, monocytes, lymphocytes) also engage adhesion molecules during transit into the airspace, it will also be important to test whether EMP2 regulates trafficking of these cells during disease, perhaps supporting beneficial cell trafficking in response to some environmental insults.
In the mouse uterus, EMP2 localizes to the apical (luminal) surface of endometrial cells at the time of blastocyst implantation (10, 45) and is thus accessible to EMP2-blocking diabodies delivered locally via the intravaginal route (15) . Anti-EMP2 antibodies are presently under preclinical investigation for cancer indications in humans (54) . We found that i.t. pretreatment of wild type mice with anti-EMP2 scFv reduced LPS-induced airspace neutrophilia (Supplemental Figure 5) . Although the effect of EMP2 blockade on neutrophilia was modest under the conditions that we tested, further optimization may be possible. We propose that EMP2 targeting in the lung, potentially with the use of topical (inhaled) agents, may possibly offer a novel, selective therapeutic strategy against lung diseases driven by acute (acute lung injury), chronic (chronic obstructive pulmonary disease), or recurrent (bronchiectasis) excessive PMN delivery to the airspace. Unlike agents under development that block PMN trafficking indiscriminately (e.g., CXCR2 antagonists), such a strategy should avoid systemic immunosuppression. EMP2 mutations have recently been identified that underlie childhoodonset nephrotic syndrome (55) , and may do so through caveolin dysregulation (31) . Given this,
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we propose that genetic variation in EMP2 should now also be examined in relation to human lung disease.
Taken together, our findings suggest that AT1 cells, heretofore primarily considered in the context of gas exchange and ion transport, play an important role in regulating the final step of PMN delivery to the infected airspace. EMP2 interestingly supports this transfer of PMNs, but, at least in some contexts, at critical cost to epithelial barrier integrity and survival of the host.
Methods
Mice. Emp2 -/-mice have been described (14) and were on a C57BL/6 background. Age-and sex-matched WT littermate controls were used. In a subset of experiments C57BL/6 controls were used (Jackson Laboratory, Bar Harbor, ME). were serially diluted and plated on tryptic soy agar (TSA) plates. In other studies, mice were exposed to aerosolized Escherichia coli 0111:B4 LPS (300 μg/mL, Sigma-Aldrich, St. Louis, MO) for 30 min, as previously reported (17) . For airspace analysis, BALF was spun at 300xg for 6 min. Cells were then resuspended in PBS and counted. Cytospins were stained and differentials counted by light microscopy. In order to evaluate peritoneal trafficking of PMNs, mice were injected intraperitoneally with 0.5 μg CXCL1, and euthanized 4h later for peritoneal lavage.
Generation of bone marrow chimeric mice.
Procedures were followed as previously described (17) . Emp2 +/+ mice that were congenic for CD45 (stock no. 002014; Jackson Laboratory) were used. Recipients were lethally irradiated (900 rad) by a Model 431 irradiator using a 137Cs source (JL Shepherd and Associates, San Fernando, CA). Within 4 hours after irradiation, donor-derived bone marrow from femurs and tibias (2×10 6 cells) was injected i.v. into recipients. The efficiency of donor stem cell engraftment was determined by flow cytometry for CD45.1 (Emp2 +/+ ) 9 weeks after transfer on circulating PMNs (Gr-1+) and B lymphocytes (B220+). Engraftment efficiency within all experimental animals was greater than 90%.
Chimeras were used a minimum of 12 weeks post-transplant.
Flow cytometry and fluorescence-activated cell sorting. Lung tissues were perfused, digested, and processed to single cell suspension as previously reported (56) . Cells were blocked with anti-mouse CD16/32 (2.4G2, Biolegend) and stained for 30 min with antibodies against: CD47 (miap301), ICAM-1 (3E2) and Integrin beta 3 (HMβ3-1), all purchased from BD Biosciences. In some studies, cells were stained with 1 μg/ml cholera-toxin B-Alexa Fluor 488 (Thermo Fisher Scientific) to stain lipid rafts, as previously described (24) . All flow cytometry analyses were performed on the LSR II (BD Biosciences) and analyzed using FACSDiva (BD) and FlowJo software (Tree Star). For cell sorting, lungs were perfused, inflated, and digested with elastase (Worthington Biochemicals) for 45 min at 37°C. Minced lung was then digested with DNase (Sigma, St. Louis, MO) for 15 min. Cells were strained (70 μm filter), depleted of CD45 + cells using AutoMACS column (Miltenyi Biotec), and then blocked with anti-mouse CD16/CD32 (2.4G2) and normal mouse and rat serum (Jackson ImmunoResearch). Cells were incubated with one or more of the following antibodies/markers: CD31 (390), CD34 (MEC14.7) from eBioscience/Thermo Fisher Scientific, and CD45 (104), EpCAM/CD326 (G8.8), , T1/podoplanin (8.1.1), MHCII (AF6-120.1), as well as 7-AAD, all puchased from Biolegend. AT1 (CD45 − CD31 − CD34 − EpCAM int T1α + MHCII − ), AT2 (CD45 − CD31 − CD34 − EpCAM int T1α − MHCII + ), and airway epithelial cells (CD45 − CD31 − CD34 − EpCAM hi MHCII − ), so identified as per a prior report (57), were then sorted on an ARIA-II flow cytometer (BD Biosciences) with purity >92-97%. In some experiments, CD45 -EpCAM + cells were grown in tissue culture plates for up to 9 days to induce AT1-like cells, as previously reported (58) . Rat alveolar epithelial cells were purified from lung as previously reported (59) and cultured over multiple days.
Quantitation of pulmonary interstitial PMNs. A reported procedure was followed with minor modifications (60) . In brief, LPS-exposed mice were injected i.v. with10 μg FITC-conjugated anti-CD45 (clone 30-F11) 5 minutes prior to sacrifice. Euthanized mice were exsanguinated via cardiac puncture, and then underwent BAL with ~2-3 mL 1x PBS and pulmonary vascular perfusion with ~10 mL 1x PBS. Lavaged and perfused lungs were excised and minced in the presence of 100 μg/mL unlabeled anti-CD45 (clone 30-F11) and digested in a cocktail of liberase/DNase/collagenase XI/hyaluronidase (60 min, 37ºC), followed by passage through a cell strainer. After erythrocyte lysis, cells were centrifuged (1600 rpm, 5 min), blocked (5% normal mouse serum, 5% normal rat serum, and 5 ug/ml [1:100] Fc blocker in FACS buffer), stained with APC-conjugated anti-Ly6G (clone 1A8), and resuspended for flow cytometry.
Endovascular PMNs were identified as CD45 + Ly6G + and interstitial (extravascular) PMNs as CD45 -Ly6G + . In pilot studies, we confirmed that no intravitally-labelled (CD45 + ) PMNs were detectable in BALF.
Live lung slice imaging. Lungs (N=3-4 mice/genotype) were harvested, sliced, stained (anti-CD31, -CD324/E-cadherin, and -Ly-6G), and imaged by confocal laser scanning microscope (Zeiss LSM 880), as previously described (61) .
Immunofluorescence studies of fixed lung tissue. Lung tissue was fixed, embedded in paraffin, sectioned, and immunostained for GFP (abcam #ab13970), EMP2 (rabbit serum, a kind gift from Dr. Madhuri Wadehra), SPC (Santa Cruz sc-7706), T1α (University of Iowa Developmental Studies Hybridoma Bank #8.1.1), CCSP (62), and acetylated tubulin (Sigma T7451), as previously described (63) . Images were captured on a Leica SP5 confocal or a Zeiss Axioplan 2.0 microscope.
Quantitative RT-PCR. Total RNA was extracted from cells and tissues with RNeasy kits (Qiagen) using the manufacturer's protocol. For tissue-extracted RNA, tissues were homogenized with a TissueLyser (Qiagen). For sorted lung epithelial cells or cultured primary AT1-like cells, the RNAqueous-Micro Total RNA Isolation kit (Thermo Fisher Scientific) was used with elution in a 20 μl volume. Generally, 100-1000 ng RNA was converted to cDNA and used to perform qPCR reactions on Applied Biosystems™ ViiA™ 7 in duplicate. Pre-developed, validated primer/probe sets (Applied Biosystems) were used. The efficiency (slopes) of the target amplification and the efficiency of the reference endogenous control (GAPDH) amplification were 100% (±10%).
Cell lines and generation of stable cells.
Cell lines Calu-3, NCI-H292 were purchased from ATCC, and Let1 cells were a gift from Dr. Paul Thomas at St. Jude Hospital (26) . CMT 64 cells were purchased from Sigma. For stable knockdown of EMP2 in Calu-3 and NCI-H292, lentiviral-based pLKO vectors that carry scrambled or EMP2-targeted shRNA were purchased from Sigma-Aldrich to transduce both cell lines. Stable transduced cells were selected and maintained in medium containing 2ug/ml puromycin (InvivoGen). Doxycycline-inducible Cav2 knockdown cells were generated in the EMP2 knockdown Calu-3 stable line by transduction of a lentiviral vector EZ-Tet-pLKO-Blast (Addgene, (64)) that express caveolin 2 shRNA targeting sequence (TRCN0000123022; TRCN0000296146). To express EMP2 wildtype or mutants in Let1 cells, EMP2 cDNA was purchased, and point mutations were introduced to CRAC or CARC sites in EMP2 DNA sequence and then cloned into lentiviral vector pLV-EF1a-IRES-Puro (Addgene). Let1 cells were transduced by established lentiviral constructs with puromycin selection at a concentration of 2 ug/ml.
In vitro studies of neutrophil transepithelial migration. Blood was collected from normal, healthy human donors. Procedures were followed as previously reported, with minor modifications (65) . Briefly, Calu-3 cells (0.55x10 6 /well) (65) were seeded on the undersurface of polycarbonate membranes in Transwell tissue culture inserts (Corning) and then grown to confluence (transepithelial resistance ≥1,000 Ωꞏcm 2 ). Three million human neutrophils, freshly isolated by discontinuous plasma-Percoll gradient centrifugation (66), were added to the upper chamber, and 0.5 nM fMLP (Sigma-Aldrich) was added to the lower chamber. Transmigration was allowed to proceed for 30-150 min, after which PMNs were quantified in the lower chamber with a quantitative myeloperoxidase assay (67).
Fluorescence microscopy. Cultured cells were stained with cholera toxin B and imaged by microscopy as previously reported (41) .
Cytokine analysis. Cytokines were quantified by multiplex assay (Bio-Plex; Bio-Rad Laboratories) or ELISA (eBioscience).
BALF protein measures.
The manufacturer's instructions (Pierce) were followed for the BCA protein assay, with colorimetric reading at OD562 on a Bio-Tek Synergy 2 microplate reader.
Albumin and IgM were quantified by ELISA (Bethyl).
Immunoblotting. For detection of EMP2 protein, cell lysates were treated with PNGase (New England Biolabs; 60 min, 37ºC) as previously reported (14) . Equal protein mass from cell lysates was run on a 10% sodium dodecyl sulfate-polyacrylamide gel and transferred to a PVDF membrane using standard methods. The membrane was probed with rabbit anti-EMP2 
